Research programme: BET inhibitors - Zenith Epigenetics

Drug Profile

Research programme: BET inhibitors - Zenith Epigenetics

Alternative Names: NexVas Autoimmune (AI) programme - Resverlogix; NexVas vascular inflammation; NexVas VI (vascular inflammation) therapy - Resverlogix; RVX-297; ZEN-3118; ZEN-3212; ZEN-3228; ZEN-3293; ZEN-3309; ZEN2135; ZEN222; ZEN297; ZEN3317

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Resverlogix Corporation; Zenith Epigenetics Corp
  • Developer Zenith Epigenetics Corp
  • Class Small molecules
  • Mechanism of Action BRD4-protein-inhibitors; Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Canada (PO)
  • 05 Jun 2017 Zenith Epigenetics has patent protection for its BET bromodomain inhibitors, in USA
  • 24 Sep 2014 Preclinical trials in Cancer in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top